Bioimmunate Technologies

Company Overview

Snapshot

Founded in July 2014 by Sigalit Carmel, MD, PhD, Bioimmunate Technologies operates with 1–10 employees. The company has raised $1.95M across two funding rounds. In September 2019, Bioimmunate Technologies secured a Seed round.

Business overview

Bioimmunate Technologies is a medical device company specializing in precision blood filtering technology for select autoimmune diseases. Its platform technology initially targets patients with multiple sclerosis (MS) by developing unique biological filters anchored inside special particles. These filters are designed to recognize, capture, and remove harmful MS-related cells from a patient's blood before they reach the central nervous system. The company aims to provide safer, more cost-effective therapies without side effects, operating within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.

Company Intelligence Q&A

Who founded Bioimmunate Technologies?

Bioimmunate Technologies was founded by Sigalit Carmel, MD, PhD, who also serves as the CEO.

What is Bioimmunate Technologies' primary focus?

Bioimmunate Technologies focuses on developing precision blood filtering medical technology for autoimmune diseases, with an initial focus on treating multiple sclerosis (MS).

What is the core technology developed by Bioimmunate Technologies?

The company has developed unique biological filters anchored inside special particles that recognize, capture, and remove harmful cells from patients' blood, preventing them from reaching the central nervous system.

What is the total capital raised by Bioimmunate Technologies?

Bioimmunate Technologies has raised a total of $1.95M across two funding rounds.